Dry Eye Syndrome Treatment Market To Reach $9.20 Billion By 2030

Dry Eye Syndrome Treatment Market Growth & Trends

The global dry eye syndrome treatment market size is estimated to reach USD 9.20 billion by 2030, expanding at a CAGR of 6.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to factors such as the increasing use of screens, the rising geriatric population, and a heightened prevalence of eye diseases.

The heightened use of devices with a screen, surging use of computers, and a decreased number of blinks are subsequently leading to the growth of evaporative dry eye syndrome globally. For instance, as per Frontiers Journal in 2021, when compared to pre-pandemic years, the use of screens has increased by 60-80% in adults during the COVID-19 pandemic. The exposure to the screen leads to a 66% decreased blinking rate, thus escalating the evaporation of tears and leading to dry eye disease.

Over-the-counter (OTC) products predominate the marketplace due to the extremely low acceptance of prescription products. For instance, only 10% of the diagnosed population is on prescription therapies, while 75% of the population has never tried prescription therapy. However, the number of patients diagnosed with dry eye syndrome accounts for 5-35% of overall ophthalmologist visits.

Moreover, existing products such as Xiidra and Restasis take months or weeks to demonstrate effects. In addition, as per eye consultants, these products have tolerability issues and a failure rate of as high as 50%. This depicts an unmet need in the market and is anticipated to create a lucrative opportunity for pipeline products expected to launch in the upcoming years. Moreover, regulations associated with the drugs further hamper the growth of the overall market. For instance, in 2020, Novartis had to voluntarily withdraw the use of Xiidra in Europe after regulators raised major objections to its use of xiidra.

Innovations and strategic initiatives by key players are driving the market. New product launch is a common strategy being used by the players. For instance, in October 2021, Tyrvaya (varenicline solution) nasal spray by Oyster Point Pharma was approved by the FDA as an alternative treatment approach.

 Request a free sample copy or view the report summary: Dry Eye Syndrome Treatment Market Report

Dry Eye Syndrome Treatment Market Report Highlights

• By type, Evaporative dry eye syndrome segment dominated the market with the largest market share in 2024 and is also anticipated to grow with the fastest CAGR during the forecast period

• Based on dosage form, The eye drops/ solutions segment dominated the market with the largest share of 64.68% in 2024

• By drug, The Xiidra segment dominated the overall market in 2024, with a revenue share of 8.52%.

• Based on distribution channel, online pharmacies are expected to grow at the fastest rate over the forecast period due to the increased consumer preference for online pharmacies owing to the convenience

• North America dominated the market in 2023 due to the high prevalence of the disease, surging awareness, and enhanced treatment rate

Dry Eye Syndrome Treatment Market Segmentation

Grand View Research has segmented the global Dry Eye Syndrome Treatment market based on type, drugs, product, dosage form, sales channel, distribution channel, and region:

Dry Eye Syndrome Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• Evaporative Dry Eye Syndrome

• Aqueous Deficient Dry Eye Syndrome

Dry Eye Syndrome Treatment Drugs Outlook (Revenue, USD Million, 2018 - 2030)

• Xiidra

• Restasis

• Cequa

• Tyrvaya

• Eysuvis

• Others

Dry Eye Syndrome Treatment Product Outlook (Revenue, USD Million, 2018 - 2030)

• Artificial Tears

• Cyclosporine

• Topical Corticosteroids

• Punctal Plugs

• Oral Omega Supplements

• Others

Dry Eye Syndrome Treatment Dosage Form Outlook (Revenue, USD Million, 2018 - 2030)

• Eye Drops/ Solutions

• Ointments and Gels

• Capsules & Tablets (For Supplements)

• Other Dosage Forms

Dry Eye Syndrome Treatment Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Prescription

• OTC

• Others

Dry Eye Syndrome Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Retail Pharmacies

• Hospital Pharmacies

• Online Pharmacies

Dry Eye Syndrome Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Dry Eye Syndrome Treatment Market

• Novartis AG

• AbbVie, Inc.

• Sun Pharmaceutical Industries Ltd.

• Santen Pharmaceutical Co Ltd.

• AFT Pharmaceuticals

• Johnson & Johnson Services, Inc.

• Otsuka Pharmaceutical Co., Ltd. (subsidiary of Otsuka Holdings Co., Ltd.)

• OASIS Medical

• Oyster Point Pharma, Inc. (acquired by Viatris Inc. in January 2023)

• Bausch Health Companies, Inc.